ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Next generation sequencing improves detection of drug resistance mutations in infants after PMTCT failure.
 PMID: 25542470       2015       Journal of clinical virology
Abstract: RESULTS: Of 15 infants, tested at a median age of 3.4 months after birth, 2 (13%) had non-nucleoside reverse transcriptase inhibitor (NNRTI) DRMs (K103N and Y181C) by bulk sequencing, whereas PGM detected 4 (26%) and MiSeq 5 (30%).
Introduction: A recent study found good correlation of Roche 454 sequencing for K103N and Y181C, when screening PMTCT exposed children (less than 2 years of age) prior to cART initiation.
Result: For the infant with K103N, detected by bulk sequencing, both Ion PGM and MiSeq additionally detected V106A/M and Y181C DRMs.


  Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
 PMID: 25626145       2015       European journal of medicinal chemistry
Abstract: Additionally, 7d demonstrated weak activity against the double mutant HIV-1 strain (K103N + Y181C), and was more efficient than NVP in a RT inhibition assay.


  Prevention of mother-to-child HIV-1 transmission in Burkina Faso: evaluation of vertical transmission by PCR, molecular characterization of subtypes and determination of antiretroviral drugs resistance.
 PMID: 25630709       2015       Global health action
Abstract: Genetic mutations were also isolated that induce resistance to ARV such as M184V, Y115F, K103N, Y181C, V179E, and G190A.
Introduction: have already emphasized the context by which PMTCT led to resistance mutations induced by nevirapine (NVP; V8IV, K103N, V179E, and Y
Table: Y181C


  A novel mutation, D404N, in the connection subdomain of reverse transcriptase of HIV-1 CRF08_BC subtype confers cross-resistance to NNRTIs.
 PMID: 25637519       2015       The Journal of antimicrobial chemotherapy
Abstract: Double mutations Y181C/D404N and Y181C/H221Y significantly reduced susceptibility to NNRTIs.
Abstract: The most pronounced resistance to NNRTIs was observed with the triple mutation Y181C/D404N/H221Y.


  High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.
 PMID: 25659108       2015       PloS one
Result: In contrast the Y181C mutation was found in 47.1% (n = 32) and 6.5% (n = 6) of the NVP and EFV group respectively (aRR 0.16 95% CI 0.08-0.35.
Table: Y181C


  Effects of HIV-1 reverse transcriptase connection subdomain mutations on polypurine tract removal and initiation of (+)-strand DNA synthesis.
 PMID: 25662223       2015       Nucleic acids research
Introduction: K103N or Y181C) (reviewed in).


  Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants.
 PMID: 25700160       2015       Journal of medicinal chemistry
In
Introduction: Although flexible diarylpyrimidine inhibitors (DAPYs) etravirine and rilpivirine maintain potency over Y181C variants, several first-generation inhibitors, such as nevirapine and efavirenz, suffer from ~63- and 12-fold changes in potency against RT (Y181C) compared with RT (WT).
Introduction: Among several variants identified in the clinic, mutations at the Y181 position are highly prevalent and exist as single variants, such as RT (Y181I), RT (Y181V), and RT (Y181C), as well as the double variant RT (K103N/Y181C).


  Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine.
 PMID: 25704446       2015       Clinical microbiology and infection
Abstract: Most prevalent RPV-RAMs after nevirapine experience were Y181C and H221Y, whereas L100I+K103N, Y188L and K101E occurred most in efavirenz-experienced patients.


  Characterization of HIV drug resistance mutations among patients failing first-line antiretroviral therapy from a tertiary referral center in Lusaka, Zambia.
 PMID: 25754408       2015       Journal of medical virology
Abstract: Analysis of reverse transcriptase revealed M184V (88%), K103N/S (32%), and Y181C/I/V (41%) DRMs, with the latter conferring reduced susceptibility to the salvage therapy candidates etravirine and rilpivirine.
Result: Of note, there was a high prevalence of Y181C/I/V (n = 28, 41% cumulatively) that confers reduced susceptibility to both rilpivirine (RPV) and etravirine (ETR), and Y188L (n = 5, 7%) which leads to reduced susceptibility to RPV.
Result: The most prevalent NNRTI mutations were Y181C/I/V (n = 24, 35%), (n = 3, 4%), and (n = 1 (1%), respectively, K103N/S (n = 21 (32%) and n = 1 [1%]),  PMID: 25788547       2015       Journal of clinical microbiology
Abstract: ARMS-PCR's limits of detection for mutations M184V, T215Y/F, K103N, and Y181C were <75 copies/ml, 143 copies/ml, 143 copies/ml, and 836 copies/ml, respectively.
Abstract: The ARMS-PCR assay was able to detect M184V, T215Y/F, K103N, and Y181C mutations with sensitivities of 96.8%, 85.7%, 91.3%, and 70%, respectively, and specificities of 90.6%, 95%, 100%, 96.9%, respectively, compared with data on sequencing.



Browser Board

 Co-occurred Entities




   Filtrator